Current clinical trials targeting elevated D-2HG levels, particularly in cancers with IDH mutations such as gliomas, acute myeloid leukemia, and chondrosarcomas, have demonstrated favorable responses to IDH-mutant selective inhibitors [62–64]. Here, IDH2 is linked to central nervous system cancer.